This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Frost & Sullivan: European HIV Diagnostics Manufacturers Need To Target Large, Undiagnosed HIV Population

LONDON, Feb. 20, 2013 /PRNewswire/ -- Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of novel nucleic acid test (NAT) and non-NAT technology based platforms offers growth potential for HIV diagnostics manufacturers.

New analysis from Frost & Sullivan (, Analysis of European HIV Diagnostics Market, finds that the market is estimated to expand from $797.1 million in 2012 to approximately $1,164.4 million in 2019. The research covers HIV NAT diagnostics and immunodiagnostics.

"Rising public awareness about HIV is boosting test volumes," notes Frost & Sullivan Senior Research Analyst K. Srinivas Sashidhar. "This has motivated the development of new products based on NAT and non-NAT technology platforms. The introduction of such innovative diagnostics products will be the key success factor in this market."

Heightened interest in companion diagnostics and the adoption of automation in laboratories will reinforce market growth.

"There is a significant need for highly sensitive HIV/AIDS assays in the market, which can detect very low levels of viral RNA copies," comments Sashidhar. "Companies are developing automated platforms to remain competitive."

In addition, there is a greater need to recognise the correlation between virus mutations and the efficacy of various antiretroviral therapies (ARTs). Companion diagnostics are a key solution to understanding this correlation.

"Viral genotyping is a popular trend to determine mutations in the HIV genome as they mostly lead to drug resistance," adds Sashidhar. "These demands will spur innovation, while driving market growth throughout the forecast period."

For a variety of reasons, the level of undiagnosed population in Europe remains quite high. The biggest challenge for market participants is thus to identify and tap into this segment.

Proper education and awareness will help boost test volumes and demand for HIV diagnostic kits. Effective, low-cost offerings, together with a wide range of services including periodic kit demonstrations, can advance market prospects.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs